Precision Biosciences Inc (DTIL)

Jan 10, 2025, 2:18 PM EST - 7 days ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 9, 2025, 10:01 AM EST - 8 days ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 8 days ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Dec 18, 2024, 7:01 AM EST - 4 weeks ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Nov 21, 2024, 7:01 AM EST - 2 months ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 15, 2024, 7:00 AM EST - 2 months ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 4, 2024, 7:01 AM EST - 2 months ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 29, 2024, 7:01 AM EDT - 2 months ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 28, 2024, 7:01 AM EDT - 2 months ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 24, 2024, 4:15 PM EDT - 3 months ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 8:47 AM EDT - 3 months ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Oct 21, 2024, 7:01 AM EDT - 3 months ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Oct 16, 2024, 7:01 AM EDT - 3 months ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Oct 3, 2024, 7:01 AM EDT - 3 months ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 30, 2024, 7:01 AM EDT - 3 months ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Sep 20, 2024, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:15 AM EDT - 4 months ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Sep 4, 2024, 7:01 AM EDT - 4 months ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Sep 3, 2024, 7:01 AM EDT - 4 months ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Aug 9, 2024, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Aug 1, 2024, 7:15 AM EDT - 6 months ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Jul 29, 2024, 4:15 PM EDT - 6 months ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Jul 8, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Jul 1, 2024, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Jun 27, 2024, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Jun 20, 2024, 7:00 AM EDT - 7 months ago

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.

Jun 5, 2024, 7:01 AM EDT - 8 months ago

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

May 30, 2024, 7:00 AM EDT - 8 months ago

Precision BioSciences to Participate in Upcoming June Investor Conferences

May 13, 2024, 7:00 AM EDT - 8 months ago

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:15 AM EDT - 9 months ago

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 7, 2024, 4:30 PM EDT - 9 months ago

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 7, 2024, 8:30 AM EDT - 9 months ago

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 7, 2024, 8:00 AM EDT - 9 months ago

iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 1, 2024, 7:05 AM EDT - 9 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Apr 16, 2024, 4:15 PM EDT - 9 months ago

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Apr 4, 2024, 11:00 AM EDT - 10 months ago

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

Mar 27, 2024, 6:45 AM EDT - 10 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:30 PM EDT - 10 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Mar 19, 2024, 7:00 AM EDT - 10 months ago

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Mar 6, 2024, 8:45 AM EST - 11 months ago

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Mar 1, 2024, 6:30 AM EST - 11 months ago

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Feb 29, 2024, 4:01 PM EST - 11 months ago

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Feb 20, 2024, 7:00 AM EST - 11 months ago

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Feb 14, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Feb 13, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Feb 12, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

TGTX

Feb 9, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences to Effect a Reverse Stock Split

Jan 10, 2024, 7:36 AM EST - 1 year ago

TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

TGTX

Jan 9, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

TGTX